ConcertAI, Caris Life Sciences, and AbbVie Collaborate to Enhance AbbVie’s Research and Development Efforts Towards Cancer Treatment
Shots:
- ConcertAI & Caris Life Sciences has signed a multi-year agreement with AbbVie to delve into and support AbbVie’s precision medicine-driven research and development & clinical trial optimization for cancer treatment
- Under the terms of the agreement, AbbVie will receive the rights to use Caris’ expansive real-world, multi-modal database in oncology & ConcertAI’s research-grade clinical data across various cancer indications
- In addition, AbbVie will be able to improve cancer clinical trials and patient enrolment by deploying AI/ML learning in combination with ConcertAI & Caris' clinical network & laboratory capabilities
Ref: Caris Life Sciences | Image: AbbVie
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Shivani is a content writer at PharmaShots. She has a keen interest in recent innovations in the life sciences industry. She covers news related to Product approvals, clinical trial results, and updates. She can be contacted at connect@pharmashots.com.
